奥他万古霉素通过破坏金黄色葡萄球菌和耐万古霉素肠球菌的细胞膜完整性来实现快速杀菌。
Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing.
机构信息
The Medicines Company, 7170 Frederick Banting, St. Laurent, Quebec, Canada H4S 2A1.
出版信息
Antimicrob Agents Chemother. 2010 Dec;54(12):5369-71. doi: 10.1128/AAC.00760-10. Epub 2010 Sep 27.
Abstract
Oritavancin is an investigational lipoglycopeptide in clinical development for the treatment of acute bacterial skin and skin structure infections. In this study, we demonstrate that oritavancin causes bacterial membrane depolarization and permeabilization leading to cell death of Gram-positive pathogens and that these effects are attributable to the 4'-chlorobiphenylmethyl group of the molecule.
摘要
奥他万古霉素是一种临床开发中的糖肽类抗生素，用于治疗急性细菌性皮肤和皮肤结构感染。在这项研究中，我们证明奥他万古霉素可导致革兰氏阳性病原体的细胞膜去极化和通透性增加，从而导致细胞死亡，而这些作用归因于该分子的 4'-氯联苯甲基基团。
相似文献
1
Oritavancin disrupts membrane integrity of Staphylococcus aureus and vancomycin-resistant enterococci to effect rapid bacterial killing.
Antimicrob Agents Chemother. 2010 Dec;54(12):5369-71. doi: 10.1128/AAC.00760-10. Epub 2010 Sep 27.
2
Ultrastructural effects of oritavancin on methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus.
Antimicrob Agents Chemother. 2009 Feb;53(2):800-4. doi: 10.1128/AAC.00603-08. Epub 2008 Nov 24.
3
In vitro activity of oritavancin and comparator agents against staphylococci, streptococci and enterococci from clinical infections in Europe and North America, 2011-2014.
Int J Antimicrob Agents. 2015 Dec;46(6):674-81. doi: 10.1016/j.ijantimicag.2015.08.014. Epub 2015 Oct 20.
4
Use of in vitro vancomycin testing results to predict susceptibility to oritavancin, a new long-acting lipoglycopeptide.
Antimicrob Agents Chemother. 2015 Apr;59(4):2405-9. doi: 10.1128/AAC.05098-14. Epub 2015 Feb 9.
5
Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
J Antimicrob Chemother. 2009 Jun;63(6):1191-9. doi: 10.1093/jac/dkp126. Epub 2009 Apr 15.
6
Oritavancin: mechanism of action.
Clin Infect Dis. 2012 Apr;54 Suppl 3:S214-9. doi: 10.1093/cid/cir920.
7
Impact of human serum albumin on oritavancin in vitro activity against enterococci.
Antimicrob Agents Chemother. 2009 Jun;53(6):2687-9. doi: 10.1128/AAC.00197-09. Epub 2009 Apr 6.
8
Effect of growth phase and pH on the in vitro activity of a new glycopeptide, oritavancin (LY333328), against Staphylococcus aureus and Enterococcus faecium.
J Antimicrob Chemother. 2002 Jul;50(1):19-24. doi: 10.1093/jac/dkf058.
9
Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
Antimicrob Agents Chemother. 2009 Mar;53(3):918-25. doi: 10.1128/AAC.00766-08. Epub 2008 Dec 22.
10
Oritavancin: a novel lipoglycopeptide active against Gram-positive pathogens including multiresistant strains.
Int J Antimicrob Agents. 2010 Nov;36(5):401-7. doi: 10.1016/j.ijantimicag.2010.06.048. Epub 2010 Aug 21.
引用本文的文献
1
A Comparative Review of the Pharmacology of Dalbavancin and Oritavancin for Gram-Positive Infections: Birds of a Feather or Apples and Oranges?
Infect Dis Ther. 2025 Sep 3. doi: 10.1007/s40121-025-01215-1.
2
Glycopeptides: Insights Towards Resistance, Clinical Pharmacokinetics and Pharmacodynamics.
Indian J Microbiol. 2025 Mar;65(1):32-50. doi: 10.1007/s12088-024-01273-y. Epub 2024 Apr 27.
3
Is an oritavancin catheter lock solution active against biofilms of staphylococci and enterococci?
Heliyon. 2025 Jan 10;11(2):e41885. doi: 10.1016/j.heliyon.2025.e41885. eCollection 2025 Jan 30.
4
In silico molecular targets, docking, dynamics simulation and physiologically based pharmacokinetics modeling of oritavancin.
BMC Pharmacol Toxicol. 2024 Oct 22;25(1):79. doi: 10.1186/s40360-024-00804-z.
5
The role of long-acting antibiotics in the clinical practice: a narrative review.
Infez Med. 2023 Dec 1;31(4):449-465. doi: 10.53854/liim-3104-4. eCollection 2023.
6
The Clinical Efficacy of Multidose Oritavancin: A Systematic Review.
Antibiotics (Basel). 2023 Sep 29;12(10):1498. doi: 10.3390/antibiotics12101498.
7
Staph wars: the antibiotic pipeline strikes back.
Microbiology (Reading). 2023 Sep;169(9). doi: 10.1099/mic.0.001387.
8
Antibiotics and Carbohydrate-Containing Drugs Targeting Bacterial Cell Envelopes: An Overview.
Pharmaceuticals (Basel). 2022 Jul 29;15(8):942. doi: 10.3390/ph15080942.
9
Antibacterial activity of recently approved antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) strains: A systematic review and meta-analysis.
Ann Clin Microbiol Antimicrob. 2022 Aug 17;21(1):37. doi: 10.1186/s12941-022-00529-z.
10
Recent Developments in Methicillin-Resistant (MRSA) Treatment: A Review.
Antibiotics (Basel). 2022 Apr 29;11(5):606. doi: 10.3390/antibiotics11050606.
本文引用的文献
1
Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
Antimicrob Agents Chemother. 2009 Nov;53(11):4762-71. doi: 10.1128/AAC.00952-09. Epub 2009 Sep 8.
2
Comparative in vitro activity of oritavancin against Staphylococcus aureus strains that are resistant, intermediate or heteroresistant to vancomycin.
J Antimicrob Chemother. 2009 Oct;64(4):868-70. doi: 10.1093/jac/dkp286. Epub 2009 Aug 4.
3
Vancomycin and oritavancin have different modes of action in Enterococcus faecium.
J Mol Biol. 2009 Oct 9;392(5):1178-91. doi: 10.1016/j.jmb.2009.06.064. Epub 2009 Jul 1.
4
Oritavancin binds to isolated protoplast membranes but not intact protoplasts of Staphylococcus aureus.
J Mol Biol. 2009 Aug 14;391(2):414-25. doi: 10.1016/j.jmb.2009.06.033. Epub 2009 Jun 16.
5
Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
Antimicrob Agents Chemother. 2009 Aug;53(8):3375-83. doi: 10.1128/AAC.01710-08. Epub 2009 May 26.
6
Interactions of oritavancin, a new lipoglycopeptide derived from vancomycin, with phospholipid bilayers: Effect on membrane permeability and nanoscale lipid membrane organization.
Biochim Biophys Acta. 2009 Sep;1788(9):1832-40. doi: 10.1016/j.bbamem.2009.05.003. Epub 2009 May 18.
7
Time-kill kinetics of oritavancin and comparator agents against Staphylococcus aureus, Enterococcus faecalis and Enterococcus faecium.
J Antimicrob Chemother. 2009 Jun;63(6):1191-9. doi: 10.1093/jac/dkp126. Epub 2009 Apr 15.
8
Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists.
Am J Health Syst Pharm. 2009 Jan 1;66(1):82-98. doi: 10.2146/ajhp080434.
9
Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
Antimicrob Agents Chemother. 2009 Mar;53(3):918-25. doi: 10.1128/AAC.00766-08. Epub 2008 Dec 22.
10
Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus.
J Mol Biol. 2008 Mar 14;377(1):281-93. doi: 10.1016/j.jmb.2008.01.031. Epub 2008 Jan 17.
Zotero 插件